Fullerenes and Hydroxylated Fullerenes
Fullerenes and Hydroxylated Fullerenes have shown interesting biological activity and have been gaining interest from several fields, including the cosmetic industry. These substances are not regulated under the Cosmetic Regulation (EC) No. 1223/2009. However, there are concerns of potential absorption of nanoparticles with their use in cosmetic products. As such, the SCCS is mandated by the European Commission to assess the safety of Fullerenes and Hydroxylated Fullerenes until the end of 2021.


Fullerenes were first discovered in 1985 by researchers at Rice University in Houston (Texas, U.S.) and have received their name due to their structural resemblance to a geodesic sphere (specifically the Montréal Biosphère, designed by the architect Buckminster Fuller).

Chemically, fullerenes is a class of carbon molecules characterized by an icosohedron structure. They are molecules of carbon, containing at least 60 atoms, that can take on different shapes (tubes, spheres, ellipsoid, etc.). Hydroxylated fullerenes is the product obtained by the hydroxylation of fullerenes. Fullerenes have a wide range of different biological activities and have been subject of intensive research in several fields (particularly Fullerene C(60), also called buckminsterfullerene). Naturally occurring fullerenes have also been discovered in ancient meteorites that hit the Earth.

In cosmetics and personal care products, Fullerenes (CAS number: 99685-96-8) and Hydroxylated Fullerenes are used as antimicrobial and skin conditioning agents. Antioxidant properties are also attributed to these ingredients in open literature. Studies have shown that fullerenes have the capacity to inhibit the formation of reactive oxygen species (ROS) and that these ingredients can be helpful in the treatment of acne (acne vulgaris).


The Commission Recommendation of 2011 on the definition of nanomaterial (2011/696/EU) states that “by derogation from point 2, fullerenes, graphene flakes and single wall carbon nanotubes with one or more external dimensions below 1 nm should be considered as nanomaterials”. According to the Regulation (EC) No 1223/2009 on cosmetic products, ‘nanomaterial’ is defined as “an insoluble or biopersistant and intentionally manufactured material with one or more external dimensions, or an internal structure, on the scale from 1 to 100 nm”.

Cosmetic products containing nanomaterials must be notified by the Responsible Person (by electronic means) six months before being placed on the market (Article 16 of the Regulation). They must be authorized by the European Commission prior to their use in cosmetic and personal care products. This does not apply when the nanomaterials are used as colourants, UV-filters or preservatives and are already included in the Annexes of the European Regulation (the “positive” lists). For more information see our previous post.

The European Commission has received 19 notifications, via the CPNP (Cosmetic Product Notification Portal) for cosmetic products containing fullerenes and hydroxylated fullerenes. These ingredients are not currently regulated under the European Cosmetic Regulation (i.e., not listed in the Annexes).

This month the European Commission has issued a request for a scientific opinion on fullerenes and hydroxylated fullerenes from the Scientific Committee on Consumer Safety (SCCS) due to the potential for dermal absorption (or crossing of a mucous membranes to other cells) of nanoparticles.

The European Commission has requested for the SCCS to answer two questions:

  • Does the SCCS consider Fullerenes and Hydroxylated Fullerenes safe when used in cosmetic products according to the maximum concentrations and specifications as reported via CPNP, taking into account reasonably foreseeable exposure conditions?
  • Based on the currently available scientific literature and SCCS’ expert judgement, the SCCS is requested to assess any further scientific concerns with regard to the use of Fullerenes and Hydroxylated Fullerenes in cosmetic products and whether a potential risk to human health can be identified according to Article 16(6) Reg.1223/2009

The deadline established for the presentation of the safety assessment by the SCCS was set at six months (from the request reception).

If you wish to get more information on fullerenes or others cosmetic ingredients, do not hesitate to contact us at info@criticalcatalyst.com.


  1. Lens M. Use of fullerenes in cosmetics. Recent Pat Biotechnol. 2009;3(2):118-23.
  2. Mousavi SZ, Nafisi S, Maibach HI. Fullerene nanoparticle in dermatological and cosmetic applications. Nanomedicine. 2017 Apr;13(3):1071-1087
  3. Request for a scientific opinion on “Fullerenes and Hydroxylated Fullerenes” (CAS / EC No.:99685-96-8/628-630-7, 11538-22-7/-, 182024-42-6/-). European Commission. Available from: https://ec.europa.eu/health/sites/default/files/scientific_committees/consumer_safety/docs/sccs2016_q_060.pdf


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »